Maze Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive (Loss) Income
(in thousands, except share and per share data)
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| License revenue | $— | $167,500 |
| Operating expenses: | ||
| Research and development | 108,448 | 83,496 |
| General and administrative | 34,451 | 26,418 |
| Total operating expenses | 142,899 | 109,914 |
| (Loss) income from operations | (142,899) | 57,586 |
| Interest and other income, net | 11,779 | 4,654 |
| Change in fair value of convertible promissory notes | — | (8,837) |
| (Loss) income before income tax expense | $(131,120) | $53,403 |
| Income tax expense | — | (1,172) |
| Net (loss) income | $(131,120) | $52,231 |
| Net (loss) income attributable to common stockholders, basic and diluted (see Note 14) | $(131,120) | $3,405 |
| Net (loss) income per share attributable to common stockholders (see Note 14): | ||
| Basic | $(3.05) | $1.42 |
| Diluted | $(3.05) | $1.25 |
| Weighted-average shares used in computing net (loss) income per share attributable to common stockholders (see Note 14): | ||
| Basic | 42,976,024 | 2,396,094 |
| Diluted | 42,976,024 | 2,730,299 |
| Comprehensive (loss) income: | ||
| Net (loss) income | $(131,120) | $52,231 |
| Other comprehensive income: | ||
| Net unrealized gain on marketable securities | 110 | — |
| Comprehensive (loss) income | $(131,010) | $52,231 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.